Traits of intrauterine pathology management in the peri- and postmenopausal period

Increasing number of anovulatory cycles in the perimenopause, leading to relative hyperestrogenism, and persistent hypoestrogenism in postmenopause, increase the proliferative activity and change the endometrium morphology. That is associated with higher rates of intrauterine pathology. The prevalence of atypical hyperplasia and endometrial cancer in women of the peri- and postmenopausal periods reaches its maximum values. Therefore, one of the most important concepts of patient’s management is to exclude malignant and precancerous endometrial pathology. Significant hormonal changes leads to important confounders in diagnostic and therapeutic algorithms. It could lead to both hypo- and hyperdiagnosis. The review analyzes the main causes of abnormal uterine bleeding, the features of their clinical manifestation, taking into account probable iatrogenic causes, extrauterus and extragenital sources of spotting. This article reviews the principles of ultrasound examination, considering menstrual cycle phase, duration of menopause, hormone treatment, as well as indications for endometrial biopsy, in case of inconsistency of clinical presentation, ultrasound results, menopausal status and iatrogenic factors. We describe the relevant principles of medical correction, wait-and-see tactics and surgical treatment of abnormal uterine bleeding, both in the presence of organic pathology of the endometrium, and in its absence.

1. Munro MG, Critchley HOD, Fraser IS. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet. 2018;143(3):393–408. https://doi.org/10.1002/ijgo.12666.

2. Адамян ЛВ, Анеева ЕН, Артымук НВ, Абсатарова ЮС, Беженарь ВФ, Белокриницкая ТЕ и др. Аномальные маточные кровотечения: клинические рекомендации. 2021. 50 с. Режим доступа: https://www.medkirov.ru/docs/id/1F1907-2021/$File/%D0%90%D0%BD%D0%BE%D0%BC%D0%B0%D0%BB%D1%8C%D0%BD%D1%8B%D0%B5%20%D0%BC%D0%B0%D1%82%D0%BE%D1%87%D0%BD%D1%8B%D0%B5%20%D0%BA%D1%80%D0%BE%D0%B2%D0%BE%D1%82%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D1%8F.pdf.

3. Matthews ML. Abnormal uterine bleeding in reproductive-aged women. Obstet Gynecol Clin North Am. 2015;42(1):103–115. https://doi.org/10.1016/j.ogc.2014.09.006.

4. Astrup K, Olivarius Nde F. Frequency of spontaneously occurring postmenopausal bleeding in the general population. Acta Obstet Gynecol Scand. 2004;83(2):203–207. https://doi.org/10.1111/j.0001-6349.2004.00400.x.

5. Capmas P, Pourcelot AG, Giral E, Fedida D, Fernandez H. Office hysteroscopy: A report of 2402 cases. J Gynecol Obstet Biol Reprod (Paris). 2016;45(5):445–450. https://doi.org/10.1016/j.jgyn.2016.02.007.

6. Pandey A, Karki C, Shrivastava VR, Shrestha D, Gautam P. Study of Menopausal Symptoms using Menopause Rating Scale at a Tertiary Care Center: A Descriptive Cross-sectional Study. JNMA J Nepal Med Assoc. 2020;58(230):725–728. https://doi.org/10.31729/jnma.5200.

7. Strauss JF, Barbiery RL. Yen & Jaffe’s reproductive endocrinology: Physiology, pathophysiology, and clinical management. 7th ed. Elsevier Health Sciences; 2013.

8. Carugno J. Clinical management of vaginal bleeding in postmenopausal women. Climacteric. 2020;23(4):343–349. https://doi.org/10.1080/13697137.2020.1739642.

9. Кондриков НИ, Баринова ИВ. Патология матки. 2-е изд. М.: Практическая медицина; 2019. 352 c. Режим доступа: https://medprint.ru/978-5-98811-495-6?manufacturer_id=3342.

10. Reed SD, Newton KM, Clinton WL, Epplein M, Garcia R, Allison K et al. Incidence of endometrial hyperplasia. Am J Obstet Gynecol. 2009;200(6):678.e1–678. e6786. https://doi.org/10.1016/j.ajog.2009.02.032.

11. Gon DS, Kundu DT, Mallick DD, Ghosh DG. A Study on Histopathological Patterns of Endometrium in Different Types of Abnormal Uterine Bleeding Among Peri And Postmenopausal Women. IOSR J Dent Med Sci. 2016;15(09):106–111. https://doi.org/10.9790/0853-150905106111.

12. Abid M, Hashmi AA, Malik B, Haroon S, Faridi N, Edhi MM, Khan M. Clinical pattern and spectrum of endometrial pathologies in patients with abnormal uterine bleeding in Pakistan: need to adopt a more conservative approach to treatment. BMC Womens Health. 2014;14:132. https://doi.org/10.1186/s12905-014-0132-7.

13. Chernukha GE, Asaturova AV, Ivanov IA, Dumanovskaya MR. Endometrial lesion’s pattern in different age groups. Akusherstvo i Ginekologiya (Russian Federation). 2018;(8):129–134. (In Russ.) https://doi.org/10.18565/aig.2018.8.129-134.

14. Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016;27(1):16–41. https://doi.org/10.1093/annonc/mdv484.

15. Каприн АД, Старинский ВВ, Шахзадова АО. Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2021. 252 с. Режим доступа: https://glavonco.ru/cancer_register/%D0%97%D0%B0%D0%B1%D0%BE%D0%BB_2020_%D0%AD%D0%BB%D0%B5%D0%BA%D1%82%D1%80.pdf.

16. Кравец ОА, Кузнецов ВВ, Морхов КЮ, Нечушкина ВМ, Новикова ЕГ, Новикова ОВ и др. Рак тела матки: клинические рекомендации. 2018. 33 с. Режим доступа: https://oncology.ru/association/clinical-guidelines/2018/rak-tela-matki_pr2018.pdf.

17. Lacey JVJr, Sherman ME, Rush BB, Ronnett BM, Ioffe OB, Duggan MA et al. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol. 2010;28(5):788–792. https://doi.org/10.1200/JCO.2009.24.1315.

18. Lee SC, Kaunitz AM, Sanchez-Ramos L, Rhatigan RM. The oncogenic potential of endometrial polyps: a systematic review and meta-analysis. Obstet Gynecol. 2010;116(5):1197–1205. https://doi.org/10.1097/AOG.0b013e3181f74864.

19. Ferrazzi E, Zupi E, Leone FP, Savelli L, Omodei U, Moscarini M et al. How often are endometrial polyps malignant in asymptomatic postmenopausal women? A multicenter study. Am J Obstet Gynecol. 2009;200(3):235.e1–235. e2356. https://doi.org/10.1016/j.ajog.2008.09.876.

20. Baiocchi G, Manci N, Pazzaglia M, Giannone L, Burnelli L, Giannone E et al. Malignancy in endometrial polyps: a 12-year experience. Am J Obstet Gynecol. 2009;201(5):462.e1–462.e4624. https://doi.org/10.1016/j.ajog.2009.05.055.

21. Wolfman W. No. 249-Asymptomatic Endometrial Thickening. J Obstet Gynaecol Can. 2018;40(5):e367–e377. https://doi.org/10.1016/j.jogc.2018.03.005.

22. Practice Bulletin No. 149: Endometrial cancer. Obstet Gynecol. 2015;125(4): 1006–1026. https://doi.org/10.1097/01.AOG.0000462977.61229.de.

23. Goldstein SR, Lumsden MA. Abnormal uterine bleeding in perimenopause. Climacteric. 2017;20(5):414–420. https://doi.org/10.1080/13697137.2017.1358921.

24. Njoku K, Abiola J, Russell J, Crosbie EJ. Endometrial cancer prevention in high-risk women. Best Pract Res Clin Obstet Gynaecol. 2020;65:66–78. https://doi.org/10.1016/j.bpobgyn.2019.12.005.

25. Jayaprakasan K, Polanski L, Ojha K. Gynaecological Ultrasound Scanning. Cambridge University Press; 2020. https://doi.org/10.1017/9781108149877.

26. Wanderley MD, Álvares MM, Vogt MF, Sazaki LM. Accuracy of Transvaginal Ultrasonography, Hysteroscopy and Uterine Curettage in Evaluating Endometrial Pathologies. Rev Bras Ginecol Obstet. 2016;38(10):506–511. https://doi.org/10.1055/s-0036-1593774.

27. Vitner D, Filmer S, Goldstein I, Khatib N, Weiner Z. A comparison between ultrasonography and hysteroscopy in the diagnosis of uterine pathology. Eur J Obstet Gynecol Reprod Biol. 2013;171(1):143–145. https://doi.org/10.1016/j.ejogrb.2013.08.024.

28. Адамян ЛВ, Андреева ЕН, Артымук НВ, Башмаков НВ, Беженарь ВФ, Белокриницкая ТЕ. Гиперплазия эндометрия: клинические рекомендации. 2021. 19 с. Режим доступа: http://disuria.ru/_ld/10/1089_kr21N85MZ.pdf.

29. Dumanovskaya MR, Chernukha GE, Tabeyeva GI, Asaturova AV. Endometrial hyperplasia: search for optimal solutions and strategies. Akusherstvo i Ginekologiya (Russian Federation). 2021;(4):23–31. (In Russ.) https://doi.org/10.18565/aig.2021.4.23-31.

30. Timmermans A, Opmeer BC, Khan KS, Bachmann LM, Epstein E, Clark TJ et al. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstet Gynecol. 2010;116(1):160–167. https://doi.org/10.1097/AOG.0b013e3181e3e7e8.

31. ACOG Committee Opinion No. 734: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding. Obstet Gynecol. 2018;131(5):e124–e129. https://doi.org/10.1097/AOG.0000000000002631.

32. van der Meer AC, Hanna LS. Development of endometrioid adenocarcinoma despite Levonorgestrel-releasing intrauterine system: a case report with discussion and review of the RCOG/BSGE Guideline on the Management of Endometrial Hyperplasia. Clin Obes. 2017;7(1):54–57. https://doi.org/10.1111/cob.12168.

33. Solovyeva AV, Chegus LA. Abnormal uterine bleeding in women of reproductive age and premenopause. Akusherstvo i Ginekologiya (Russian Federation). 2020;(8):29–38. (In Russ.) https://doi.org/10.18565/aig.2020.8.29-38.

34. Hwang WY, Suh DH, Kim K, No JH, Kim YB. Aspiration biopsy versus dilatation and curettage for endometrial hyperplasia prior to hysterectomy. Diagn Pathol. 2021;16(1):7. https://doi.org/10.1186/s13000-020-01065-0.

35. Stock RJ, Kanbour A. Prehysterectomy curettage. Obstet Gynecol. 1975;45(5):537–541. Available at: https://ovidsp.dc1.ovid.com/ovid-new-b/ovidweb.cgi?T=JS&PAGE=fulltext&D=ovft&AN=00006250-197505000-00011&NEWS=N&CSC=Y&CHANNEL=PubMed.

36. Yang JH, Chen CD, Chen SU, Yang YS, Chen MJ. Factors Influencing the Recurrence Potential of Benign Endometrial Polyps after Hysteroscopic Polypectomy. PLoS ONE. 2015;10(12):e0144857. https://doi.org/10.1371/journal.pone.0144857.

37. Bedner R, Rzepka-Górska I. Hysteroscopy with directed biopsy versus dilatation and curettage for the diagnosis of endometrial hyperplasia and cancer in perimenopausal women. Eur J Gynaecol Oncol. 2007;28(5):400–402. Available at: https://article.imrpress.com/journal/EJGO/28/5/pii/2007193/400-402.pdf.

38. Gebauer G, Hafner A, Siebzehnrübl E, Lang N. Role of hysteroscopy in detection and extraction of endometrial polyps: results of a prospective study. Am J Obstet Gynecol. 2001;184(2):59–63. https://doi.org/10.1067/mob.2001.108332.

39. Singh S, Best C, Dunn S, Leyland N, Wolfman WL. No. 292-Abnormal Uterine Bleeding in Pre-Menopausal Women. J Obstet Gynaecol Can. 2018;40(5):e391–e415. https://doi.org/10.1016/j.jogc.2018.03.007.

40. Gambacciani M, Monteleone P, Ciaponi M, Sacco A, Genazzani AR. Clinical usefulness of endometrial screening by ultrasound in asymptomatic postmenopausal women. Maturitas. 2004;48(4):421–424. https://doi.org/10.1016/j.maturitas.2003.10.006.

41. Lou YY, Kannappar J, Sathiyathasan S. Unscheduled bleeding on HRT – do we always need to investigate for endometrial pathology? Int J Reprod Contraception Obstet Gynecol. 2017;6(10):4174–4178. https://doi.org/10.18203/2320-1770.ijrcog20174391.

42. Cheung KB, Cheung NYA, Ip PCP, Li HWR, Ng Pun TC, So WKW, Yim SF. Guidelines on Clinical Management of Endometrial Hyperplasia. The Hong Kong College of Obstetricians and Gynaecologists; 2015. 14 p. Available at: https://www.hkcog.org.hk/hkcog/Download/Guidelines_on_Clinical_Management_of_Endometrial_Hyperplasia.pdf.

43. Gallos ID, Alazzam M, Clark TJ, Faraj R, Rosenthal AN, Smith PP, Gupta JK. Management of Endometrial Hyperplasia: RCOG Green-top Guideline. Royal Coll; 2016. 31 p. Available at: https://www.rcog.org.uk/media/knmjbj5c/gtg_67_endometrial_hyperplasia.pdf.

44. Ivanov IA, Kostуukov KV, Chernukha GE. Echosonography’s accuracy of intrauterine pathology’s diagnostics in reproductive-age women. Meditsinskiy Sovet. 2023;(5):22–28. (In Russ.) https://doi.org/10.21518/ms2023-107.

45. Ashrafyan LA, Balan VE, Baranov II, Belaya ZhE, Bobrov SA, Vorontsova AV et al. Algorithms for menopausal hormone therapy during the period of periand postmenopause. Joint position statement of RSOG, RAM, AGE, RAOP experts. Akusherstvo i Ginekologiya (Russian Federation). 2021;(3):210–221. (In Russ.) https://doi.org/10.18565/aig.2021.3.210-221.

46. Адамян ЛВ, Андреева ЕН, Аполихина ИА, Артымук НВ, Ашрафян ЛА, Балан ВЕ и др. Менопауза и климактерическое состояние у женщины: клинические рекомендации. 2021. 85 с. Режим доступа: https://www.medkirov.ru/docs/id/21F070-2021/$File/%D0%9C%D0%B5%D0%BD%D0%BE%D0%BF%D0%B0%D1%83%D0%B7%D0%B0%20%D0%B8%20%D0%BA%D0%BB%D0%B8%D0%BC%D0%B0%D0%BA%D1%82%D0%B5%D1%80%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%BE%D0%B5%20%D1%81%D0%BE%D1%81%D1%82%D0%BE%D1%8F%D0%BD%D0%B8%D0%B5%20%D1%83%20%D0%B6%D0%B5%D0%BD%D1%89%D0%B8%D0%BD%D1%8B.pdf.

47. Dave FG, Adedipe T, Disu S, Laiyemo R. Unscheduled bleeding with hormone replacement therapy. Obstet Gynaecol. 2019;21(2):95–101. https://doi.org/10.1111/tog.12553.

48. de Medeiros SF, Yamamoto MM, Barbosa JS. Abnormal bleeding during menopause hormone therapy: insights for clinical management. Clin Med Insights Womens Health. 2013;6:13–24. https://doi.org/10.4137/CMWH.S10483.

49. Donoghue JF, McGavigan CJ, Lederman FL, Cann LM, Fu L, Dimitriadis E et al. Correction: Dilated Thin-Walled Blood and Lymphatic Vessels in Human Endometrium: A Potential Role for VEGF-D in Progestin-Induced BreakThrough Bleeding. PLoS ONE. 2021;16(10):e0259337. https://doi.org/10.1371/journal.pone.0259337.

50. Cleator SJ, Ahamed E, Coombes RC, Palmieri C. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin Breast Cancer. 2009;9(1):6–17. https://doi.org/10.3816/CBC.2009.s.001.

51. Polin SA, Ascher SM. The effect of tamoxifen on the genital tract. Cancer Imaging. 2008;8(1):135–145. https://doi.org/10.1102/1470-7330.2008.0020.

52. Pinkerton JV, Goldstein SR. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. Menopause. 2010;17(3):642–653. https://doi.org/10.1097/gme.0b013e3181c4f1d6.

53. Pronin SM, Matsneva IA, Novikova YeG. Possibilities of reproduction after treatment for early endometrial cancer. Akusherstvo i Ginekologiya (Russian Federation). 2018;(10):100–104. (In Russ.) https://doi.org/10.18565/aig.2018.10.100-104.

54. Fishman M, Boda M, Sheiner E, Rotmensch J, Abramowicz J. Changes in the sonographic appearance of the uterus after discontinuation of tamoxifen therapy. J Ultrasound Med. 2006;25(4):469–473. https://doi.org/10.7863/jum.2006.25.4.469.

55. Fergusson RJ, Bofill Rodriguez M, Lethaby A, Farquhar C. Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding. Cochrane Database Syst Rev. 2019;8(8):CD000329. https://doi.org/10.1002/14651858.CD000329.pub3.

56. AlHilli MM, Hopkins MR, Famuyide AO. Endometrial cancer after endometrial ablation: systematic review of medical literature. J Minim Invasive Gynecol. 2011;18(3):393–400. https://doi.org/10.1016/j.jmig.2011.02.004.

57. Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol. 2016;27(1):e8. https://doi.org/10.3802/jgo.2016.27.e8.

58. Abu Hashim H, Ghayaty E, El Rakhawy M. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials. Am J Obstet Gynecol. 2015;213(4):469–478. https://doi.org/10.1016/j.ajog.2015.03.037.

59. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2010;203(6):547.E1–547.E10. https://doi.org/10.1016/j.ajog.2010.07.037.

60. El Behery MM, Saleh HS, Ibrahiem MA, Kamal EM, Kassem GA, Mohamed MElS. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia. Reprod Sci. 2015;22(3):329–334. https://doi.org/10.1177/1933719114542014.

61. Auclair MH, Yong PJ, Salvador S, Thurston J, Colgan TTJ, Sebastianelli A. Guideline No. 390-Classification and Management of Endometrial Hyperplasia. J Obstet Gynaecol Can. 2019;41(12):1789–1800. https://doi.org/10.1016/j.jogc.2019.03.025.

62. Marra C, Penati C, Ferrari L, Cantù MG, Bargossi L, Fruscio R. Treatment of simple and complex endometrial non-atypical hyperplasia with natural progesterone: response rate to different doses. Gynecol Endocrinol. 2014;30(12):899–901. https://doi.org/10.3109/09513590.2014.945904.

63. Mittermeier T, Farrant C, Wise MR. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia. Cochrane Database Syst Rev. 2020;9(9):CD012658. https://doi.org/10.1002/14651858.CD012658.pub2.

64. Адамян ЛВ (ред.). Сочетанные доброкачественные опухоли и гиперпластические процессы матки (миома, аденомиоз, гиперплазия эндометрия): проект клинических рекомендаций по ведению больных. М.: Изд-во Научный центр акушерства, гинекологии и перинатологии им. В.И. Кулакова Минздрава России; 2015. 92 с.

65. American Association of Gynecologic Laparoscopists. AAGL practice report: practice guidelines for the diagnosis and management of endometrial polyps. J Minim Invasive Gynecol. 2012;19(1):3–10. https://doi.org/10.1016/j.jmig.2011.09.003.

66. Lieng M, Istre O, Qvigstad E. Treatment of endometrial polyps: a systematic review. Acta Obstet Gynecol Scand. 2010;89(8):992–1002. https://doi.org/10.3109/00016349.2010.493196.

67. Karakaya BK, Ozkan NT, Kansu-Celik H, Coskun B, Saridogan E, Evliyaoglu O. Malignancy risk of endometrial polyps among geriatric women. Int J Gerontol. 2018;12(3):215–217. https://doi.org/10.1016/j.ijge.2018.02.013.

68. Sasaki LMP, Andrade KRC, Figueiredo ACMG, Wanderley MDS, Pereira MG. Factors Associated with Malignancy in Hysteroscopically Resected Endometrial Polyps: A Systematic Review and Meta-Analysis. J Minim Invasive Gynecol. 2018;25(5):777–785. https://doi.org/10.1016/j.jmig.2018.02.004.

69. Uglietti A, Buggio L, Farella M, Chiaffarino F, Dridi D, Vercellini P, Parazzini F. The risk of malignancy in uterine polyps: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2019;237:48–56. https://doi.org/10.1016/j.ejogrb.2019.04.009.

70. Chernukha GE, Asaturova AV, Ivanov IA, Korshunov AA. Hormonal sensitivity of endometrial polyps and the efficiency of LNG-IUD as a method of their secondary prevention. Akusherstvo i Ginekologiya (Russian Federation). 2020;(6):65–71. (In Russ.) https://doi.org/10.18565/aig.2020.6.65-71.

71. Lieng M. Endometrial polyps: National Guideline approved by The Norwegian Society of Obstetrics and Gynecology. 2015. 9 p. Available at: https://www.nfog.org/files/guidelines/NFOG_Guideline_NOR_160419%20Endometrial%20polyp%20NO%20merged.pdf.

72. Vitale SG, Haimovich S, Laganà AS, Alonso L, Di Spiezio Sardo A, Carugno J. Endometrial polyps. An evidence-based diagnosis and management guide. Eur J Obstet Gynecol Reprod Biol. 2021;260:70–77. https://doi.org/10.1016/j.ejogrb.2021.03.017.